Evaluation of quinolones in experimental animal models of infections.
Many discriminative experimental animal models of infection have been utilized in the evaluation of newer fluoroquinolones. In vivo efficacy of many of the newer agents has been shown in experimental models of meningitis, endocarditis, pneumonia, urinary tract infections, pyelonephritis, osteomyelitis, abscesses of various types, septic arthritis, gastroenteritis, salmonellosis, listeriosis, tuberculosis, syphilis, sinusitis, prostatitis and burn wound sepsis, among others. This review focuses on recent developments in a few selected areas. Although the limitations of animal model studies are well described, these results provide a rationale for the appropriate clinical usage of the newer fluoroquinolones in humans.
Scheld
W M
WM
Division of Infectious Diseases, University of Virginia Health Sciences Center, University of Virginia School of Medicine, Charlottesville 22908.
D042462:4-Quinolones; D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D004697:Endocarditis, Bacterial / Q000188:drug therapy; D006801:Humans; D008581:Meningitis / Q000188:drug therapy; D010019:Osteomyelitis / Q000188:drug therapy; D011014:Pneumonia / Q000188:drug therapy
D042462:4-Quinolones; D000890:Anti-Infective Agents